

Special Issue

Recent Advances in Papillomaviruses Research

Message from the Guest Editors

Persistent infections with high risk human papillomaviruses (HPV) account for more than 600.000 newly diagnosed cancers of the anogenital and oropharyngeal tract annually. Although much information has been gathered from laboratory and clinical investigations, we still have an incomplete picture of the critical interactions of HPV with host cells and the immune system. This Special Issue on Recent Advances in Papillomaviruses Research in *Viruses* will provide a multifaceted view of the latest research into papillomaviruses. Each chapter in this series will highlight the efforts and progress made to acquire basic knowledge of HPV host interactions and will indicate particular areas that remain to be uncovered. Topics in this new series include the processes of HPV entry into keratinocytes, HPV and the DNA damage response, BRD4 proteins in the HPV life cycle, different animal papillomavirus model systems as well as updates on L2-based prophylactic vaccines and on improved HPV diagnostics.

Guest Editors

Prof. Dr. Thomas Iftner

Institute of Medical Virology, Universität Tübingen, Tübingen, Germany

Dr. Frank Stubenrauch

Institute of Medical Virology, Universität Tübingen, Tübingen, Germany

Deadline for manuscript submissions

closed (30 April 2022)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.8
CiteScore 7.3
Indexed in PubMed



mdpi.com/si/68486

Viruses
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.8
CiteScore 7.3
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

Director, HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2024).